Search Results

BostonGene today announced a master agreement with Duke University School of Medicine to collaborate on multiple research projects across lung cancer, gastrointestinal, genitourinary and skin cancers.

Daxor Corporation, the global leader in blood volume measurement technology, announces new data from Duke University Medical Center validating the benefits of blood volume analysis in optimizing individualized therapy for heart failure patients with impaired renal function.

Medable Inc., the leading technology provider for modern clinical trials, announces results from a new research project with Duke University Department of Population Health Sciences’ Bioethics and Stakeholder (BASE) Lab on the acceptability of enhanced electronic informed consent (eIC) in clinical trials.

With Alzheimer’s disease expected to afflict 12.7 million Americans by 2050, researchers at Penn State University and Duke University Medical Center are advancing our understanding of the disease’s behavior in different people – making personalized, optimized treatment possible for the first time. And they’re doing it with math.

Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced it will partner with the Duke Clinical Research Institute (DCRI) to optimize all aspects of and plan the operationalization of Saghmos’ Phase 3 study for its cardio-renal metabolic modulator ST-62516.

Lumos Pharma, Inc., a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pitukcheewanont, MD, known also as Dr. Duke, to the position of Chief Medical Officer, effective January 1, 2024.

ImmunoForge has announced on the 18th that it has expanded its license rights with Duke University to enhance joint research and drug development opportunities in relation to the elastin-like polypeptide platform technology.

Sen-Jam Pharmaceutical is pleased to announce the successful completion of participant enrollment for the clinical trial of its innovative therapeutic, SJP-002C in partnership with Duke University.

Invivyd, Inc., a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announced the appointment of William Duke as Chief Financial Officer.